GD2-GANGLIOSIDE
Modify Date: 2024-01-03 16:36:33
GD2-GANGLIOSIDE structure
|
Common Name | GD2-GANGLIOSIDE | ||
|---|---|---|---|---|
| CAS Number | 65988-71-8 | Molecular Weight | 1673.921 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 1633.3±65.0 °C at 760 mmHg | |
| Molecular Formula | C72H126N4O34 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 941.6±34.3 °C | |
| Name | GD2-GANGLIOSIDE |
|---|---|
| Synonym | More Synonyms |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 1633.3±65.0 °C at 760 mmHg |
| Molecular Formula | C72H126N4O34 |
| Molecular Weight | 1673.921 |
| Flash Point | 941.6±34.3 °C |
| Exact Mass | 1672.903564 |
| LogP | 9.76 |
| Appearance of Characters | lyophilized powder |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.598 |
| Storage condition | −20°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
|
Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes.
Neuron 82(2) , 308-19, (2014) Soluble Aβ oligomers contribute importantly to synaptotoxicity in Alzheimer's disease, but their dynamics in vivo remain unclear. Here, we found that soluble Aβ oligomers were sequestered from brain i... |
|
|
Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
Int. J. Cancer 135(9) , 2199-205, (2014) Anti-G(D2) murine antibody 3F8 plus subcutaneously (sc) administered granulocyte-macrophage colony-stimulating factor (GM-CSF) was used against primary refractory neuroblastoma in metastatic osteomedu... |
|
|
Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
J. Mol. Med. 91(4) , 459-72, (2013) Neuroblastoma (NB) is the most common extracranial solid tumor in children. Combining passive immunotherapy with an antibody to the disialoganglioside GD2 (ch14.18/SP2/0) and cytokines with 13-cis-ret... |
| Ganglioside GD2 (d18:1/9Z-18:1) |
| (2S,3R,4E)-3-Hydroxy-2-[(9Z)-9-octadecenoylamino]-4-octadecen-1-yl 5-acetamido-6-[(1S,2R)-2-({5-acetamido-3,5-dideoxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]-β-L-threo-hex-2-ulopyranonosyl}oxy)-1,3-dihy droxypropyl]-3,5-dideoxy-β-L-threo-hex-2-ulopyranonosyl-(2->3)-[2-acetamido-2-deoxy-β-D-galactopyranosyl-(1->4)]-β-D-galactopyranosyl-(1->4)-β-D-glucopyranoside |
| 9-Octadecenamide, N-[(1S,2R,3E)-1-[[[O-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl-(1->4)-O-[O(6ξ)-5-(acetylamino)-3,5-dideoxy-α-D-gluco-2-nonulopyranonosyl-(2->8)-(6ξ)-5-(acetylamino)-3,5-d ideoxy-α-D-gluco-2-nonulopyranonosyl-(2->3)]-O-β-D-galactopyranosyl-(1->4)-β-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]-, (9Z)- |